PepGen(US:PEPG)2025-11-12 13:02Clinical Trials - The 15 mg/kg cohort of the FREEDOM study demonstrated a mean splicing correction of 53.7%, the highest reported to date in DM1 patients [3]. - All patients in the 5 mg/kg cohort of the FREEDOM2 trial have been enrolled and received at least one dose, with results expected in Q1 2026 [4]. - The company expects to initiate dosing in the 10 mg/kg cohort of the FREEDOM2 trial in Q1 2026, with results anticipated in the second half of 2026 [4]. - PGN-EDODM1 has received Orphan Drug and Fast Track Designations from the U.S. FDA for the treatment of DM1 [9]. Financial Performance - The company raised $115 million in a public offering, extending its cash runway into the second half of 2027 [8]. - Cash, cash equivalents, and marketable securities totaled $163.7 million as of September 30, 2025, compared to $120.2 million at the end of 2024 [20]. - Research and Development Expenses were $13.4 million for the three months ended September 30, 2025, down from $17.7 million in the same period in 2024, a decrease of approximately 24% [8]. - General and Administrative Expenses were $5.2 million for the three months ended September 30, 2025, slightly down from $5.4 million in the same period in 2024 [8]. - The net loss for the three months ended September 30, 2025, was $18.0 million, or $(0.52) per share, compared to a net loss of $21.4 million, or $(0.66) per share, for the same period in 2024 [8]. - Total operating expenses for the three months ended September 30, 2025, were $18.7 million, down from $23.2 million in the same period in 2024, a reduction of approximately 19% [18].